Respiratory Syncytial Virus Infections
Conditions
Keywords
Ribavirin, RSV
Brief summary
The purpose of this study is to test the safety and effectiveness of ribavirin, administered as an aerosol, in preventing progression of upper respiratory tract RSV infection to RSV pneumonia in bone marrow and peripheral blood transplant recipients.
Detailed description
The study enrolls 90 transplant recipients with positive nasal/throat culture specimens for Respiratory Syncytial Virus (RSV) infection. Patients are randomized into one of two groups: investigational treatment or standard treatment.
Interventions
DRUGVirazole (Ribavirin) Inhalation Solution
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
5 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* 2 years of age or older. * Are not pregnant or breast-feeding and agree to use a reliable birth control method for the duration of the study. * Are a blood or bone marrow transplant recipient. * Have evidence of upper respiratory tract infection. * Have nasopharyngeal-throat samples positive for RSV.
Exclusion criteria
* Are known to be HIV positive. * Have pneumonia. * Require a ventilator to breathe. * Are pregnant. * Are breast-feeding and are unwilling to stop breast-feeding. * Are receiving treatment with certain other drugs for RSV.
Countries
United States
Outcome results
None listed